SOUTH SAN FRANCISCO, California, Oct. 2 (TNSrep) -- Genentech, a member of the Roche Group, issued the following news release:

* * *

Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

* Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populat . . .

Click here for more information about our products